KemPharm (KMPH) Misses Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
KemPharm, Inc. Reports Q3 2015 Results
November 12, 2015 4:17 PM ESTRecent Clinical Development Highlights:
Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from second intranasal human abuse liability clinical trial of KP201/APAP Reported positive data demonstrating tamper-resistant properties of KP201/APAP Anticipate filing a new drug application (NDA) for KP201/APAP in Q4 2015Recent Product and Financial Highlights:
Initiated the development of an APAP-free formulation of KP201 as well as the development of an immediate release (IR) formulation of KemPharm's oxycodone prodrug,... MoreKemPharm, Inc. Reports Q3 2015 Results
November 12, 2015 4:17 PM ESTRecent Clinical Development Highlights:
Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from second intranasal human abuse liability clinical trial of KP201/APAP Reported positive data demonstrating tamper-resistant properties of KP201/APAP Anticipate filing a new drug application (NDA) for KP201/APAP in Q4 2015Recent Product and Financial Highlights:
Initiated the development of an APAP-free formulation of KP201 as well as the development of an immediate release (IR) formulation of KemPharm's oxycodone prodrug,... More